MonoSol Rx

MonoSol Rx, BiondVax Collaborate on Oral-film Flu Vaccine

The companies are working to develop a needle-free delivery method for the M-001 universal flu vaccine.

MonoSol Rx, LLC ("MonoSol Rx"), the developer of PharmFilm drug delivery technology, announced today that it has entered into a partnership with BiondVax, an Israeli based pharmaceutical company, to develop an oral film formulation of BiondVax' universal flu vaccine, M-001, utilizing MonoSol Rx's PharmFilm delivery platform. There are significant advantages for this needle free delivery in vaccines, including ease of use, increased compliance and simplified distribution.   

No votes yet
Syndicate content